Skip to content
    WST
    Earnings call· Mar 2026(Q1 FY26)

    WEST PHARMACEUTICAL SERVICES Q1 FY26 earnings call WST

    Apr 23, 2026 Source

    Executive summary

    West Pharmaceutical Services Q1 FY26 — Strong Performance Drives Raised Full-Year Guidance

    West Pharmaceutical Services reported a strong Q1 FY26, significantly exceeding revenue and EPS expectations, driven by robust HVP components growth across GLP-1 and non-GLP-1 segments. This performance led to an upward revision of full-year organic revenue and adjusted EPS guidance, reflecting continued market momentum and operational efficiencies. The company is navigating commodity cost increases and the SmartDose divestiture while focusing on long-term growth drivers like biologics and Annex 1.

    Highlights

    5

    • Q1 revenues of $845 million, up 21% reported and 15% organic, significantly exceeding expectations.

    • Adjusted EPS of $2.13, up 47% year-over-year, 45% above the midpoint of previous guidance.

    • HVP components organic growth of 23%, driven by strong GLP-1 and non-GLP-1 demand.

    • Full-year organic revenue growth guidance raised to 7%-9% (from 5%-7%) and adjusted EPS to $8.40-$8.75.

    • Adjusted operating margins expanded 350 basis points to 21.4% due to positive mix shift and operational leverage.

    Concerns

    3

    • Rising oil and commodity prices are expected to have a single-digit million net impact on full-year results after mitigation efforts.

    • The SmartDose divestiture will create a $55 million revenue headwind in the second half of FY26.

    • The roll-off of the CGM contract in the second half of FY26 represents a $40 million revenue headwind.

    Guidance & targets

    14
    CategoryTargetConfidence
    Full-year 2026 Organic Revenue Growth
    7% to 9%
    high materiality
    High
    Full-year 2026 Adjusted EPS
    $8.40 to $8.75
    high materiality
    High
    Full-year 2026 Reported Revenue
    $3.295 billion to $3.35 billion
    high materiality
    High
    Full-year 2026 HVP Components Organic Growth
    low to mid-teens
    medium materiality
    High
    Full-year 2026 Non-GLP-1 HVP Components Growth
    low double digits
    medium materiality
    High
    Full-year 2026 GLP-1 HVP Components Growth
    mid- to high teens
    medium materiality
    High
    Full-year 2026 Net Interest Income
    $7 million
    low materiality
    Medium
    Full-year 2026 Tax Rate
    19%
    low materiality
    Medium
    Full-year 2026 Diluted Shares Outstanding
    71.5 million
    low materiality
    Medium
    Q2 2026 Revenue
    $830 million to $850 million
    medium materiality
    High
    Q2 2026 Adjusted Diluted EPS
    $2.05 to $2.12
    medium materiality
    High
    Annex 1 Revenue Growth Contribution
    200 basis points
    medium materiality
    High
    Capital Expenditures
    $250 million to $275 million
    medium materiality
    High
    SmartDose Transaction Closing
    midyear
    high materiality
    High

    Segment performance

    4
    SegmentRevenueYoYQoQMargin
    Proprietary Products - HVP Components
    Driven by robust growth in both GLP-1 and non-GLP-1 revenues, including biologics and Annex 1 upgrades. Strong execution in scaling up production, particularly in Europe.
    GLP-1 revenues contribution to total company sales: 10%Non-GLP-1 HVP components revenues growth: high teensBiologics organic growth: 26%Annex 1 related projects increase: 66% YoY
    		$409 million22.6%——
    Proprietary Products - HVP Delivery Devices
    Driven by increased SmartDose 3.5 revenues in anticipation of the midyear transaction closing, as well as good performance in SelfDose and Crystal Zenith.
    		$124 million27.5%——
    Standard Products
    Partially driven by Annex 1 related conversion to HVP components, as standard products convert to HVP over time.
    		$161 million0.5%——
    West Vantage (Contract Manufacturing)
    Driven by an increase in sales of self-injected devices for obesity and diabetes. Gross margin recovered sequentially, though down slightly year-over-year due to Dublin facility ramp-up. New Dublin site is fully operational.
    		$151 million6.2%——

    Operational metrics

    10
    Total Company Gross Margin
    35.1%up 190 bps YoY
    Q1 FY26

    Commodity costs did not materially impact Q1 results.

    Adjusted Operating Margins
    21.4%up 350 bps YoY
    Q1 FY26

    Significant improvement compared to prior year.

    Capital Expenditures
    $43 milliondown from $71 million prior year
    Q1 FY26

    Reflects continued focus on increased capital spending efficiency.

    Cash and Investments Balance
    $521 million
    Q1 FY26

    Ended the first quarter with this balance.

    Share Repurchase Program Authorization
    $1 billionnew authorization
    Q1 FY26

    Authorized by the Board of Directors given strong financial position.

    Shares Repurchased
    1.2 million shares for $298 million
    Q1 FY26

    Part of returning capital to shareholders.

    Dividends Paid
    $16 million
    Q1 FY26

    Additional means of returning capital to shareholders.

    Price Contribution to Revenue Growth
    3.5
    Q1 FY26

    Contributed to overall revenue growth in the quarter.

    Annex 1 Revenue Growth Contribution
    200
    FY26

    Expected contribution from Annex 1 and HVP conversion, part of a multiyear tailwind.

    Drug Handling Business (West Vantage) Incremental Revenue
    $20 million
    FY26

    Most of this incremental revenue will be in the back half of the year, with significant ramp-up expected through 2027.

    Industry KPIs

    4
    MetricValueDetails
    Revenue EPS guidanceFY organic revenue growth 7%-9%; Adjusted EPS $8.40-$8.75%; USD
    China revenue exposure—
    Pricing price realization3.5percentage points
    Segment organic revenue growth22.6% (HVP components); 27.5% (HVP delivery devices); 0.5% (Standard Products); 6.2% (West Vantage)%

    Product announcements

    1
    ProductTypeDetails
    Dublin West Vantage sitelaunch

    Deals & partnerships

    1
    Not statedDivestiture of SmartDose 3.5 business

    The company continues to expect to close the SmartDose transaction midyear. SmartDose 3.5 revenues increased in Q1 in anticipation of this transaction.

    Risks & headwinds

    4
    Macro environment dynamismremainder of FY26

    N/A

    Mitigation: Prudent forecasting, taking it one quarter at a time.

    Rising oil and commodity pricesFY26

    single-digit millions net impact

    Mitigation: Working to offset costs through various means, including hedging; operations and supply chain not affected.

    SmartDose divestitureH2 FY26

    $55 million revenue headwind

    Mitigation: Adjusted full-year 2026 expected organic growth rate to account for these revenues.

    CGM contract roll-offH2 FY26

    $40 million headwind

    Mitigation: Factored into full-year guidance, contributing to a more first-half weighted revenue profile.

    What to watch in Q2 FY26

    5

    SmartDose divestiture completion

    Midyear
    CurrentExpected midyear
    TargetClosed

    Why it matters

    Completion of the divestiture will finalize the revenue impact and strategic focus for the company's delivery devices segment.

    We continue to expect to close the SmartDose transaction midyear.

    Q&A highlights

    8

    What is driving the acceleration in non-GLP-1 HVP components growth, specifically regarding biologics, biosimilars, and Annex 1?

    Management attributed the strong non-GLP-1 HVP growth to increased market demand in biologics and biosimilars (26% organic growth), the ramp-up of Annex 1 projects (up 66% YoY), and operational excellence in HVP manufacturing. They noted this is a continuation of momentum from the second half of the previous year.

    “As you see, this is a continuation of what we saw in the second half of the year of this real continued momentum in the HVP non-GLP-1 components business. And to Eric's point, what we've seen is a real combination of not only demand, the benefit of the positive mix associated with upgrading to [indiscernible], and we expect both of those things to continue as well as the continued market development of the biologics business.”

    asked by Patrick Donnelly · answered by Robert McMahon

    2 min read6 chapters

    Detailed Narrative

    01

    HVP Components Drive Strong Performance

    The Proprietary Products segment, particularly HVP components, was a key growth driver, achieving 23% organic growth in Q1. This was fueled by significant performance in both GLP-1 and non-GLP-1 revenues, with GLP-1 contributing 10% of total company sales. Non-GLP-1 HVP components grew in the high teens, driven by biologics, biosimilars, and Annex 1 upgrades, demonstrating broad-based demand and market strength.

    02

    Operational Excellence and Capacity Expansion

    West is leveraging operational excellence initiatives across its HVP manufacturing sites, notably in Europe. These efforts include accelerated employee onboarding, temporary redeployment of team members, and global network optimization. These actions have led to increased production output and better utilization of existing capacity, contributing to the better-than-expected performance and providing confidence for future demand.

    03

    Annex 1 as a Multi-Year Tailwind

    The Annex 1 regulatory transition continues to be a significant opportunity, with projects increasing sequentially and up 66% compared to the prior year. Management anticipates a 200 basis points revenue growth contribution in 2026 from Annex 1 and HVP conversion. The company sees potential for this tailwind to extend beyond Europe, driven by increasing global regulatory focus on contamination and customer standardization.

    04

    West Vantage Segment and Dublin Site Launch

    The West Vantage (Contract Manufacturing) segment grew 6% organically in Q1. The new Dublin West Vantage site is now fully operational and producing commercial product, marking a significant expansion of global capabilities. This site supports high-volume injectable therapies, including those for obesity and diabetes, and incorporates a more profitable drug handling business, which is meeting expectations in its early stages.

    05

    Capital Allocation and Shareholder Returns

    West demonstrated a strong commitment to shareholder returns, authorizing a new $1 billion share repurchase program. In Q1, the company repurchased 1.2 million shares for $298 million and paid out $16 million in dividends. The robust cash flow and strong balance sheet position the company well for continued capital deployment for growth and value creation.

    06

    Navigating Headwinds and Strategic Divestiture

    While performance was strong, the company is prudently managing rising oil and commodity prices, expecting a single-digit million net impact after mitigation. The anticipated mid-year divestiture of the SmartDose business will result in a $55 million revenue headwind in H2 FY26, and the roll-off of a CGM contract will add another $40 million headwind, which are factored into the updated guidance.

    AI-generated summary of the company’s earnings call. Not investment advice.